Animals have co-evolved with diverse communities of microorganisms that are integral to the development and activity of their immune and nervous systems1. Alterations in the composition and function of the community of gut microorganisms (termed the microbiota) are increasingly being implicated in neurological disorders that involve neuroinflammation, including multiple sclerosis2, autism spectrum disorder3 and Parkinson’s disease4. Studies are also emerging that link the gut microbiota to amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive loss of motor neurons crucial for movement, speech and cognition. This devastating disease is usually fatal within a few years of diagnosis. Writing in Nature, Burberry et al.5 fill some gaps in our knowledge of how gut microbes might contribute to ALS, from studies of the condition in a mouse model. Their findings might help to shed light on how a gene linked to ALS called C9orf72 affects this disease.
Initial studies6,7 have shown that the gut microbiota of people who have ALS differ from those of unaffected individuals. A study of a mouse model of the disease, based on an ALS-associated mutation in the Sod1 gene6, has provided strong evidence that alterations in the microbiota can exacerbate neurodegeneration and drive early mortality. That study also identified microbes and microbial molecules that promote improved motor function and longer lifespan in the mice. It showed that the particular positive or negative effects observed might depend on differences in the microbes encountered in the animals’ housing facility (termed a vivarium). Mouse models of inflammatory diseases have also revealed that the animals’ environment has such an effect8.
Burberry et al. used a mouse model of ALS (Fig. 1) in which the animals have a mutant version of the gene C9orf72, resulting in a deficiency in the encoded C9orf72 protein (these mice also model a neurodegenerative condition called frontotemporal dementia). The authors observed that if the animals were reared in the Harvard University animal facility, they had a shorter lifespan, exacerbated movement problems and an elevated immune response (as indicated by the presence in their blood of pro-inflammatory molecules called cytokines and autoimmune antibodies), compared with mice reared at the Broad Institute of Harvard and MIT. After excluding diet, light cycles and other environmental factors as being responsible for this difference, the authors compared the microbial profiles for the animals in the two facilities, and found that a virus called murine norovirus and the bacteria Helicobacter, Pasteurella pneumotropica and Tritrichomonas muris were more common at the Harvard facility than at the Broad facility.
The authors investigated the diversity of the gut microbial species further by analysing faecal samples and sequencing a bacterial gene needed for synthesis of the ribosome, the cell’s protein-production machinery. This revealed that the ALS mice housed at Harvard or Johns Hopkins University (where mice had a short lifespan) had less microbiota diversity than did mice housed at the Broad or at the Jackson Laboratory research institute (where mice had a longer lifespan). Microbiota profiling of bacterial species revealed alterations in the relative abundances of 62 of 301 bacterial taxa assessed when the ALS mice reared at Harvard and Johns Hopkins were compared with the mice reared at the Jackson Labs and the Broad.
The authors next investigated whether the gut microbiota contributed to the vivarium-dependent differences in the severity of symptoms observed for these animals. They tested the effects of antibiotic treatment and of transplants of faecal microbiota on the inflammation and autoimmune responses of the mice reared at Harvard. Antibiotic treatment of young mice as they aged prevented the induction of pro-inflammatory cytokines and reduced other hallmarks of inflammation — such as a rise in the number of immune cells called neutrophils, the presence of autoimmune antibodies and enlargement of the spleen. Antibiotic treatment of aged mice had a similar effect. Inflammation in the Harvard mice was also reduced if they received transplants of faecal microbiota from animals housed at the Broad.
To explore whether the microbiota contributed to neuroinflammation in the spinal cord in these mice, animals reared at Harvard were continuously treated with antibiotics. The authors assessed whether inflammation had developed by checking for infiltration of immune cells into the spinal cord and whether the spinal cord contained immune cells called microglia in an activated state. They found that infiltration by neutrophils and by subsets of immune cells called CD3e+ T cells was reduced, as was microglial activation, compared with the situation in untreated animals. These findings are consistent with the results of studies of other disease models, indicating a role for the gut microbiota in modulating inflammation in the central nervous system and the development and function of microglia9,10.
Burberry and colleagues have shown that alterations in the gut microbiota variously modulate how ALS-related symptoms manifest in mice deficient in C9orf72. Their results suggest that microbial modulation of inflammation outside the brain might be responsible.
More research will be needed to find the particular microbes and microbial functions involved in regulating the different effects on inflammation outside the central nervous system, and to assess whether this peripheral inflammation influences the degeneration of motor neurons in the central nervous system and the associated movement impairments that such neuronal losses cause. It will also be interesting to determine whether particular immune pathways in the central nervous system and/or outside it are responsible for the lifespan changes that occur through C9orf72 deficiency. Unravelling the molecular and cellular mechanisms involved in the neuroinflammation and neurodegeneration observed would advance our understanding of the interactions between environmental factors and genetic risk factors in ALS, and might lead to new targets for clinical intervention.
Nature 582, 34-35 (2020)
Fung, T. C., Olson, C. A. & Hsiao, E. Y. Nature Neurosci. 20, 145–155 (2017).
Berer, K. et al. Proc. Natl Acad. Sci. USA 114, 10719–10724 (2017).
Hsiao, E. Y. et al. Cell 155, 1451–1463 (2013).
Sampson, T. R. et al. Cell 167, 1469–1480 (2016).
Burberry, A. et al. Nature 582, 89–94 (2020).
Blacher, E. et al. Nature 572, 474–480 (2019).
Fang, X. et al. Front. Microbiol. 7, 1479 (2016).
Stappenbeck, T. S. & Virgin, H. W. Nature 534, 191–199 (2016).
Erny, D. et al. Nature Neurosci. 18, 965–977 (2015).
Thion, M. S. et al. Cell 172, 500–516 (2018).